Clinical Nuclear Medicine · 2015 · 47 citations · 27 references
MedicineNuclear MedicineOncologyMolecular ImagingOncologic ImagingTumor HeterogeneityCancer MetabolismMalignant NeoplasmsMetabolic EvaluationMetabolic HeterogeneityTumor CharacterizationTumor ImagingKaplan-meier Confidence IntervalsMetabolic State HeterogeneityMetabolic Tumor CharacterizationMetabolic Tumor ImagingMetabolic Tumor VolumeTotal Lesion GlycolysisTumor MetabolismUnivariate Analysis
PURPOSE: The aim of the study was to evaluate the prognostic significance of intratumoral metabolic heterogeneity on pretreatment F-FDG PET/CT in patients with lung cancer who were pathologically N0 (pN0) after curative surgical resection. METHODS: We examined 119 patients (M/F = 79/40; mean age, 64.6 ± 9.0 years) who had undergone pretreatment F-FDG PET/CT and were diagnosed as pN0 after curative surgery for adenocarcinoma (ADC; n = 67) or squamous cell carcinoma (SQCC; n = 52). Heterogeneity factor (HF) and other metabolic parameters (SUVmax, metabolic tumor volume [MTV] and total lesion glycolysis [TLG]) for the primary lesions were measured, and the results were analyzed for recurrence. The HF, defined as the derivative of the volume-threshold function from 20% to 80%, was computed for primary lesions. Univariate and multivariate analyses for recurrence were performed using the Kaplan-Meier method and using the Cox proportional hazards model. RESULTS: SUVmax, MTV, TLG, and HF were statistically different between patients with ADC and SQCC. Forty-one (34.5%) of 119 patients experienced recurrence (ADC, 25/67 = 37.3% vs. SQCC, 16/52 = 30.8%). Results of univariate analysis indicate that SUVmax, MTV, TLG, and HF in ADC and TLG and HF in SQCC were predictors for recurrence. After adjusting for sex, age, and histological grade in multivariate analysis, high SUVmax, MTV, TLG, and HF in ADC exhibited an association with increased risk of recurrence. CONCLUSIONS: Metabolic parameters and heterogeneity of primary tumor on pretreatment F-FDG PET/CT can predict recurrence in pN0 NSCLC patients of ADC type who have undergone curative surgery but not in patients of SQCC type.
27
Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text
Peter Goldstraw, John Crowley, Kari Chansky et al. · Journal of Thoracic Oncology · 2007 · 3.7K citations
Treatment of Stage I and II Non-small Cell Lung Cancer
John A. Howington, Matthew G. Blum, Andrew C. Chang et al. · CHEST Journal · 2013 · 1.4K citations
Gary M. Strauss, James E. Herndon, Michael A. Maddaus et al. · Journal of Clinical Oncology · 2008 · 990 citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Non–Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT
Balaji Ganeshan, Vicky Goh, Henry Mandeville et al. · Radiology · 2012 · 453 citations